Join us at the Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference (PDTC) in NYC from October 14-15, 2026.

Meet our neuroscience experts at PDTC to discover how Julius Clinical supports efficient, high-quality clinical trials across complex neurological and psychiatric conditions. Our team partners with sponsors to navigate the unique challenges of neuroscience drug development, delivering tailored strategies that accelerate timelines while maintaining scientific rigor.

Let’s Meet in New York!

Connect with our team at PDTC 2026 to discuss how we can support your next Parkinson’s disease clinical trial.

Name(Required)

Advancing Neuroscience Clinical Development with Confidence

P95 Julius Clinical offers comprehensive support across all phases of clinical development. With deep expertise in central nervous system diseases, we help bring innovative therapies to patients faster. From protocol development to study execution, we provide a fully integrated approach designed to optimize outcomes at every stage.

Explore our neuroscience expertise.

Why P95 Julius Clinical?

Neuroscience trials present distinct challenges, from complex endpoints to patient variability and recruitment barriers. P95 Julius Clinical combines scientific expertise with operational precision to address these challenges effectively.

With our strong global network and experienced in-house teams, we deliver customized solutions aligned with your development goals, ensuring high-quality data and reliable study execution.